Celyad Oncology SA
ISIN: BE0974260896 | Ticker: CYAD | LEI: 549300ORR0M8XF56OI64
Country: Belgium
Celyad Oncology is a biotechnology company focused on the research and discovery of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.
Year founded2004
Served areaWorldwide
HeadquartersAxis Business Park Rue Edouard Belin 2, 1435 Mont-Saint-Guibert, Brabant wallon – Belgium
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 66,084,000.00 | 79,943,000.00 | 19,716,000.00 |
| Noncurrent Assets | N/A | 46,379,000.00 | 45,651,000.00 | 4,891,000.00 |
| Property Plant And Equipment | N/A | 4,119,000.00 | 3,248,000.00 | 309,000.00 |
| Noncurrent Receivables | N/A | 2,117,000.00 | 2,209,000.00 | 0.00 |
| Other Noncurrent Assets | N/A | 293,000.00 | 262,000.00 | 264,000.00 |
| Current Assets | N/A | 19,705,000.00 | 34,292,000.00 | 14,825,000.00 |
| Trade And Other Current Receivables | N/A | 615,000.00 | 668,000.00 | 1,118,000.00 |
| Cash and cash equivalents | 39,338,000.00 | 17,234,000.00 | 30,018,000.00 | 12,445,000.00 |
| Shortterm Investments Classified As Cash Equivalents | N/A | 0.00 | 0.00 | 0.00 |
| Current Assets Other Than Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners | N/A | N/A | 0.00 | 245,000.00 |
| Other Current Assets | N/A | 1,711,000.00 | 2,211,000.00 | 1,017,000.00 |
| Equity And Liabilities | N/A | 66,084,000.00 | 79,943,000.00 | 19,716,000.00 |
| Equity | 45,619,000.00 | 30,994,000.00 | 43,639,000.00 | 4,317,000.00 |
| Issued Capital | N/A | 48,513,000.00 | 78,585,000.00 | 78,585,000.00 |
| Retained Earnings | N/A | -283,039,000.00 | -308,997,000.00 | -349,947,000.00 |
| Share Premium | N/A | 43,349,000.00 | 6,317,000.00 | 6,317,000.00 |
| Other Reserves | N/A | 30,958,000.00 | 33,172,000.00 | 34,800,000.00 |
| Capital Redemption Reserve | N/A | 191,213,000.00 | 234,562,000.00 | 234,562,000.00 |
| Noncurrent Liabilities | N/A | 23,256,000.00 | 22,477,000.00 | 4,973,000.00 |
| Noncurrent Provisions For Employee Benefits | N/A | 614,000.00 | 53,000.00 | 13,000.00 |
| Noncurrent Advances | N/A | 4,220,000.00 | 5,851,000.00 | 4,584,000.00 |
| Other Noncurrent Liabilities | N/A | 371,000.00 | 164,000.00 | 258,000.00 |
| Longterm Borrowings | N/A | 0.00 | 0.00 | 0.00 |
| Current Liabilities | N/A | 11,834,000.00 | 13,827,000.00 | 10,426,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 4,736,000.00 | 6,611,000.00 | 4,752,000.00 |
| Current Advances | N/A | 371,000.00 | 362,000.00 | 437,000.00 |
| Other Current Liabilities | N/A | 5,614,000.00 | 5,952,000.00 | 5,100,000.00 |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 5,000.00 | 0.00 | 0.00 |
| Other Income | 4,731,000.00 | 4,909,000.00 | 9,360,000.00 |
| Profit Loss From Operating Activities | -16,987,000.00 | -26,391,000.00 | -40,857,000.00 |
| Finance Income | 217,000.00 | 144,000.00 | 185,000.00 |
| Finance Costs | 434,000.00 | 255,000.00 | 198,000.00 |
| Profit Loss Before Tax | -17,204,000.00 | -26,502,000.00 | -40,870,000.00 |
| Income Tax Expense Continuing Operations | 0.00 | 10,000.00 | 65,000.00 |
| Profit (loss) | -17,204,000.00 | -26,512,000.00 | -40,935,000.00 |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -17,204,000.00 | -26,512,000.00 | -40,935,000.00 |
| Adjustments For Provisions | N/A | 858,000.00 | 29,000.00 | 2,171,000.00 |
| Adjustments For Sharebased Payments | N/A | 2,782,000.00 | 2,172,000.00 | 1,624,000.00 |
| Other Adjustments For Noncash Items | N/A | -933,000.00 | 328,000.00 | -1,447,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -27,665,000.00 | -26,643,000.00 | -28,010,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 150,000.00 | 331,000.00 | 123,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 169,000.00 | 62,000.00 | 0.00 |
| Cash Flows From Used In Investing Activities | N/A | 157,000.00 | -126,000.00 | 7,202,000.00 |
| Proceeds From Issuing Shares | N/A | 0.00 | 36,568,000.00 | -124,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 429,000.00 | 280,000.00 | 230,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 1,255,000.00 | 1,099,000.00 | 896,000.00 |
| Proceeds From Government Grants Classified As Financing Activities | N/A | 7,272,000.00 | 4,369,000.00 | 4,491,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 5,396,000.00 | 39,521,000.00 | 3,241,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | 8,000.00 | 32,000.00 | -6,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | -22,112,000.00 | 12,752,000.00 | -17,567,000.00 |
| Cash and cash equivalents | 39,338,000.00 | 17,234,000.00 | 30,018,000.00 | 12,445,000.00 |
Please note that some sums might not add up.
BE0974260896
LEI549300ORR0M8XF56OI64
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.